Necrosis of uveal melanoma post-COVID-19 vaccination

Wagle, Ajeet M.; Bo, Wu; Gopal, Lingam; Sundar, Gangadhara

doi:10.4103/ijo.ijo_3040_21

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17][18] Interestingly, more data are available on the remarkable ocular adverse effects (ADEs) of COVID-19 vaccines. Angle-closure glaucoma is 1 of the 3 most frequent ADEs with AZD-1222, [19] and case reports related to this ADEs [20][21][22][23] have arisen, although there is a short interval between the injection and the onset of ADEs.…”

Section: Introductionmentioning

confidence: 99%

Mendelian randomization supports causality between COVID-19 and glaucoma

Chen,

Zhang,

Yao

et al. 2024

Medicine

View full text Add to dashboard Cite

To determine whether there is a causal relationship between Corona Virus Disease 2019 (COVID-19) and glaucoma, a 2-sample Mendelian Randomization (MR) design was applied with the main analysis method of inverse-variance-weighted. The reliability of the results was checked using the heterogeneity test, pleiotropy test, and leave-one-out method. Four sets of instrumental variables (IVs) were used to investigate the causality between COVID-19 and glaucoma risk according to data from the IEU Genome Wide Association Study (GWAS). The results showed that 2 sets of COVID-19(RELEASE) were significantly associated with the risk of glaucoma [ID: ebi-a-GCST011071, OR (95% CI) = 1.227 (1.076–1.400), P = .002259; ID: ebi-a-GCST011073: OR (95% CI) = 1.164 (1.022–1.327), P = .022450; 2 sets of COVID-19 hospitalizations were significantly associated with the risk of glaucoma (ID: ebi-a-GCST011081, OR (95% CI) = 1.156 (1.033–1.292), P = .011342; ID: ebi-a-GCST011082: OR (95% CI) = 1.097 (1.007–1.196), P = .034908)]. The sensitivity of the results was acceptable (P > .05) for the 3 test methods. In conclusion, this MR analysis provides preliminary evidence of a potential causal relationship between COVID-19 and glaucoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Mendelian randomization supports causality between COVID-19 and glaucoma

Chen,

Zhang,

Yao

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Singh

Parmar

Ichhpujani

2022

Preprint

View full text Add to dashboard Cite

Objective: To evaluate glaucoma cases reported post-COVID-19 vaccination and describe the clinical presentations in these cases. Design: An analysis of the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) database Participants: The study includes 161 individuals who were reported for glaucoma after administration of COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Janssen)] between December 2020 and April 2022. Main Outcome Measures: Estimated crude reporting rate of glaucoma, clinical presentations, onset duration and associated risk factors. Results: A total of 2,061,557,270 doses of COVID-19 vaccines were administered during the study timeframe. During this period, 161 glaucoma cases were reported with an estimated crude reporting rate (per million doses) of 0.09, 0.06 and 0.07 for BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively. The majority of patients (n=130, 80.7%) received BNT162b2, vaccine, while 27 patients (16.8%) received mRNA-1273 and four patients (2.5%) received rAd26.COV2.S vaccines. The mean age of patients in the cohort was 60.41+/-17.56 years and 67.7% (n=109) were women. More than half (56.6%) were reported within the first week after vaccination. The glaucoma onset interval was significantly shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273 (p=0.013). A higher risk of glaucoma incidence was observed in the short term in patients who received BNT162b2 vaccines compared to mRNA-1273 (p=0.05). In patients vaccinated with mRNA-1273, a significantly higher frequency of glaucoma cases was reported in older patients (p=0.047) compared to younger age groups. Conclusions: The CDC-VAERS data suggest an extremely low safety concern for glaucoma on receiving BNT162b2, mRNA-1273, or Ad26.COV2.S vaccines. The onset interval of adverse events was shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273. The glaucoma cases after mRNA-1273 vaccination were more commonly reported in older patients. These findings are subject to the limitations of passive reporting systems, under reporting and presumptive case definition, and should be considered preliminary without the medical record analysis for establishing a definitive diagnosis.

show abstract

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

et al. 2022

View full text Add to dashboard Cite

Background: To counter the rapidly spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global vaccination efforts were initiated in December 2020. We assess the risk of glaucoma following SARS-CoV-2 vaccination and evaluate its onset interval and clinical presentations in patients. Methods: We performed a retrospective analysis of the glaucoma cases reported to the Vaccine Adverse Event Reporting System (VAERS) database between 16 December 2020, and 30 April 2022. We assessed the crude reporting rate of glaucoma, clinical presentations, onset duration, and associated risk factors. Results: During this period, 161 glaucoma cases were reported, with crude reporting rates (per million doses) of 0.09, 0.06, and 0.07 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The mean age of the patients was 60.41 ± 17.56 years, and 67.7% were women. More than half (56.6%) of the cases were reported within the first week of vaccination. The cumulative-incidence analysis showed a higher risk of glaucoma in patients who received the BNT162b2 vaccines compared with mRNA-1273 (p = 0.05). Conclusions: The incidence of glaucoma following vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S is extremely rare. Amongst the patients diagnosed with glaucoma, the onset interval of adverse events was shorter among those who received the BNT162b2 and rAd26.COV2.S vaccines compared with mRNA-1273. Most glaucoma cases were reported within the first week following vaccination in female patients and from the fifth to seventh decade. This study provides insights into the possible temporal association between reported glaucoma events and SARS-CoV-2 vaccines; however, further investigations are required to identify the potential causality link and pathological mechanisms.

show abstract

Necrosis of uveal melanoma post-COVID-19 vaccination

Cited by 3 publications

References 10 publications

Mendelian randomization supports causality between COVID-19 and glaucoma

Mendelian randomization supports causality between COVID-19 and glaucoma

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

Contact Info

Product

Resources

About